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ABSTRACT
PURPOSE: Graves’ ophthalmopathy (GO) is a common cause of morbidity in patients with Graves’ disease 
which suboptimal management is widespread. Immunosuppressive drugs and orbital irradiation represent 
treatment options for patients with moderate to severe and active GO. The aim of this study is to share our 
initial results from the application of orbital radiotherapy in GO. 
MATERIAL AND METHODS: Fifteen consecutive patients (12 women and 3 men) at a mean age 52 years 
(range, 26 to 62 years) with GO underwent radiotherapy of posterior orbit. Research team included a radio-
therapist, endocrinologist and ophthalmologist performing the first and the follow-up examinations. Both 
orbits were examined for soft tissue and cornea involvement, proptosis, eye muscle impairment, visual acu-
ity, visual fields and tonometry. Ophthalmic index was calculated before and after treatment. All the pa-
tients had received glucocorticoids before radiotherapy as 46,67% of them required corticosteroids during 
the period of irradiation and 80% received antithyroid medication. Overall clinical response was evaluated 
as excellent, good, fair or no response according to Donaldson’s criteria.  
RESULTS: Fifteen patients completed the study with a follow-up of two or more months. All of them re-
ceived 20 Gy to both orbits. The overall clinical response was excellent in two patients (13,33%), good in sev-
en (46,67%), fair in five (33,33%), and there was no response in one patient (6,67% of the cases). The mean 
ophthalmopathy index (OI) was 7,2 before treatment and 3 after irradiation. There was a mean OI improve-
ment of 4,2 points (range 2-7) compared to the pretreatment values. Best response was achieved for corne-
al involvement, soft tissue symptoms, sight loss and eye muscle impairment, while the response for propto-
sis was limited. No late adverse effects associated with radiotherapy such as cataract and radiation-induced 
retinopathy were observed at all. 
CONCLUSION: Our study proved that orbital radiotherapy is an effective and safe treatment option for pro-
gressive GO with better results in the early and acute stage of the disease.
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INTRODUCTION
Graves’ ophthalmopathy (GO) develops in 20-
40% of the patients with Graves’ disease (11). Most of 
them do not require intensive treatment and watchful 
waiting is a better approach. There is a spontaneous 
regression in cases with mild symptoms (9). Howev-
er, 5-15% of the patients present with moderate to se-
vere manifestations connected with sight threatening 
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symptoms such as progressive and persistent disease, 
severe inflammatory signs, severe dyplopia, corneal 
exposure, optic nerve compression, or increased oc-
ular tension. These patients require intensive treat-
ment (1,3).
Recent studies on GO pathogenesis support the 
hypothesis of аutoimmune reaction against a shared 
or a cross-reactive thyroid orbit antigen. Orbital fi-
broblasts activated by T-lymphocytes produce gly-
cosaminoglycans and their accumulation causes tis-
sue edema and increases orbital volume. Radiation 
therapy has been used to treat thyroid eye disease 
with recognition of its antiinflammatory effect (2,6). 
Two other major treatment modalities are corticoste-
roids and surgical decompression (4,7). Immunosup-
pressive drugs, immunoglobulins, plasmapheresis 
and octreotide have been proposed, too (3,10). 
Guidance on retrobulbar irradiation for thyroid 
eye disease from the National Institute for Health 
and Clinical Excellence (NICE) concludes that cur-
rent evidence on the safety and efficacy of retrobul-
bar irradiation for thyroid eye disease appears ade-
quate to support the use of this procedure in patients 
for whom other treatments are inadequate or associ-
ated with significant side effects.
This study reports our initial results from the 
application of orbital radiotherapy mainly in GO 
non-responders or GO patients in whom corticoste-
roid therapy is contraindicated. 
MATERIAL AND METHODS
For a period of one year, sixteen consecutive pa-
tients with moderate to severe GO underwent radio-
therapy of posterior orbit in the Department of Ra-
diotherapy, Regional Oncological Hospital of Shou-
men. Eligibility criteria included a more than two-
month-long follow-up and a complete ophthalmic 
examination to calculate ophthalmopathy index (OI) 
before and after treatment. One patient was exclud-
ed from the analysis due to insufficient follow-up du-
ration, less than one month while the rest 15 patients 
completed the study. There were 12 women and 3 
men aged between 26 and 62 years (mean age of 52 
years). Ophthalmopathy duration ranged between 6 
and 26 months (mean duration of 10 months). Thy-
roid function assessment during radiotherapy re-
vealed hyperthyroidism in 12 patients (80%) while 
two patients (13,33%) were euthyroid and one patient 
(6,67%) was hypothyroid. All the patients were previ-
ously given local and systemic corticosteroids for the 
ophthalmopathy, seven patients (46,67%) required 
corticosteroids during the period of radiotherapy 
and 12 patients (80%) received antithyroid medica-
tion. Surgery had been applied in the rest three pa-
tients (20% of the cases). Two patients (13,33%) had 
a history of cataract and one patient was operated on 
for glaucoma before radiotherapy. 
A multidisciplinary team including a radio-
therapist, an endocrinologist and an ophthalmolo-
gist performed the first and the subsequent exami-
nations. Both orbits were examined for signs of pro-
ptosis displacement of the globe and by tonometry. 
The ocular fundus, visual acuity, visual fields and eye 
movements were assessed, too. We used ultrasound 
and CT scanning to clearly delineate orbital struc-
tures. Eye changes were numerically scored accord-
ing to OI criteria of Stanford Scoring System (Table 
1). Patient’s ophthalmological status was examined 
prior to, one and two months after treatment as well 
as every three months thereafter. Overall clinical re-
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sponse was evaluated as excellent, good, fair or no re-
sponse according to Donaldson’s criteria. In the eval-
uation of the therapeutic results for each ophthalmic 
parameter, complete response (CR) was defined as 
complete improvement (grade 0) according to Stan-
ford Scoring System criteria. Partial response (PR) 
was defined as certain reduction of grade and no re-
sponse (NR) as no change of grade.
Patients were treated in supine position using 
individual immobilization devices (Fig. 1). 
The margins of the bony orbit, lens position and 
pituitary fossa were drawn on to the outline using 
CT scan data and lateral simulator films. For irradia-
tion of the posterior orbit, a pair of lateral 60Co half-
beam block fields with custom shielding was used to 
reduce the dose to the healthy tissues (Fig. 2). A typ-
ical dose distribution was presented on Fig. 3. Dose 
prescription at the isocentre of the formed fields at 
the mid depth was 20 Gy in 10 fractions given in two 
weeks.
RESULTS
Fifteen patients followed-up for two or more 
months were eligible for analysis. All of them 
received 20 Gy to both orbits. All the patients had 
been referred because of progressive eye symptoms 
or life threatening complication after a high 
cumulative dose of corticosteroids (5) including two 
hemorrhages from gastric ulcer, one diabetes mellitus 
with worsening control, one patient of hypokaliemia 
with paroxysmal tachyarrhythmia, and one deep 
vein thrombosis of the leg. According to the leading 
eye symptoms, the patients were subdivided in 
the following groups: 93% with progressive soft 
tissue symptoms, 100% with proptosis, 93,33% 
with restriction of the gaze, 80% with eye muscle 
impairment, 53,33% with corneal abnormalities, and 
46,67% with worsening vision.
Fig. 1. Individual immobilization device during  
60Co radiotherapy
Fig. 2. Lateral 60Co half-beam block fields used to reduce 
the dose in the healthy tissues during posterior orbit 
irradiation 
Fig. 3. Dose distribution in the treatment area
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Patient’s responses as a function of each 
pathological parameter two months after 
radiotherapy were summarized in Table 2. The 
overall clinical response was excellent in two patients 
(13,33%), good in seven (46,67%), fair in five (33,33%), 
and there was no response in one patient (6,67% of the 
cases). A rapid improvement after treatment which 
occurred in some cases with excellent and good 
results was associated with short GO duration. Mean 
OI was 7,2 before treatment and 3 after irradiation. 
There was a mean OI improvement of 4,2 points 
(range 2-7) compared to the pretreatment values. 
At the time of radiotherapy, seven patients 
were on corticosteroids, but only one patient was 
continuing this treatment at the last following-up visit. 
Six out of seven patients with increased intraocular 
tension before radiotherapy improved and five of 
them had normal tension without any medication. 
None of ten patients with a relatively long following-
up of 6-15 months presented with recurrence of any 
eye symptoms. Proptosis was slightly improved in 
two patients after 8 and 10 months, respectively. 
Treatment response for each ophthalmic 
parameter was presented in Table 2 and Fig. 4. Out of 
14 patients with soft tissue symptoms before radiation, 
six showed CR, six showedd PR, and two showed NR. 
The mean initial soft tissue score decreased by 64%, 
from 2,2 to 0,8. All the patients had proptosis before 
radiotherapy and only three of them had CR, eight 
had PR and four had NR. The mean initial proptosis 
score decreased less than the soft tissue one - by 43%, 
from 2,3 to 1,3. Eye muscle impairment occurred in 
14 patients. Six patients achieved CR, four - PR and 
four - NR. Corneal involvement and vision loss were 
observed in eight and seven patients, respectively 
while CR was achieved in six and four patients, PR in 
zero and two ones, and NR in two patients and one 
patient, respectively. The best response was observed 
for corneal involvement, soft tissue signs, vision loss 
and eye muscle impairment, while the response for 
proptosis was limited. Neither late adverse effects, 
nor complications associated with radiotherapy such 
as cataract and radiation-induced retinopathy were 
registered at all. 
DISCUSSION
Our results from the application of posterior 
orbit irradiation in the patients with progressive and 
acute GO indicate that this method provides an ef-
fective and prompt regression of major symptoms af-
ter unsatisfactory response to corticosteroid therapy. 
We applied the scoring system of Stanford University 
in spite of criticism by several authors (3,9). 
The best response to irradiation is in the cate-








soft tissue 14 2,2 (2-3) 0,8 (0-2) -1,4 (64%)
proptosis 15 2,3 (1-3) 1,3 (0-3) -1,0 (43%)
eye muscle 14 1,6 (1-3) 0,6 (0-1) -1,0 (63%)
cornea 8 1,1 (1-2) 0,2 (0-1) -0,9 (82%)
vision 8 1,5 (1-3) 0,5 (0-2) -1,0 (67%)
total score 15 7,2 (4-12) 3,0 (0-7) -4,2 (58%)
Table 2. Comparison of initial and final OI (n=15)
Fig. 4. Treatment response for each ophthalmic 
parameter: S (soft tissue symptoms), P (proptosis),  
E (eye muscle impairment), C (corneal involvement),  
V (vision loss)
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concordance with other authors’ results (6,8,10). Soft 
tissue symptoms improve in 87% of our patients with 
relatively short following-up. There is an improve-
ment or stabilization of proptosis in 73% of the cas-
es. There is improvement or stabilization of the eye 
muscle impairment, corneal findings, and vision in 
71%, 75%, and 86% of the patients, respectively. 
Larger trials with long-term following-up dem-
onstrate subjective and objective improvement one 
year or even more after the irradiation. Our prelimi-
nary results are encouraging and we expect the clin-
ical response to the radiotherapy to be complete-
ly manifested with time. For this reason, ophthal-
mic surgery should be withheld until patients dem-
onstrate a plateau in their response to radiotherapy 
(5,10). 
Besides our results prove that the patients at the 
early stage of the disease more likely achieve excel-
lent or good therapeutic results than those with more 
advanced symptoms and longer history. There is a 
correlation between the objective response, i. e. low 
final OI score and the subjective one, i. e. patient’s 
satisfaction, too.
Our subgroups with or without glucocorticoid 
treatment are too small to conclude which   treatment 
approach is superior: concomitant radiation and cor-
ticosteroids or radiotherapy alone. The combination 
of these treatment modalities is considered more ef-
fective than either treatment alone, however, ran-
domized clinical trials are still lacking (12). 
CONCLUSION
Our study reveals that orbital radiotherapy is 
an effective and safe treatment option for progressive 
GO, with 93% overall response rate, the same patient 
satisfaction rate, and without any acute and long-
term complications. This method should be used 
more often and at the early and acute stage of the 
disease.
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